In addition, the role of COMP in predicting immunotherapy responses for colon cancer patients was assessed using the TIDE algorithm and verified in several ICB treatment cohorts, such as breast cancer and aRCC; however, we did not conduct the analysis in colon cancer patients receiving immunotherapy because of the absence of transcriptome data. This evidence concerns the gene COMP and colonic neoplasm.